1. Scrip
  2. >>Drug Pricing

PBMs, FTC and IRA: Experts Tackle Pharma’s Tough Acronyms At BioFuture

 
• By Jessica Merrill

Some of the industry’s biggest challenges – and potential solutions to those problems – were hot topics at the BioFuture conference in New York.

(Shutterstock)

New policies on drug pricing implemented by the US government under the Inflation Reduction Act (IRA), the Federal Trade Commission (FTC)’s actions on M&A, and the thorny role of pharmacy benefit managers (PBMs) in the US drug reimbursement system were some of the topics that came up during the BioFuture conference in New York City on 27 October.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

 
• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

Trump Executive Order On Drug Pricing Is A Mixed Bag For Pharma

 
• By Mandy Jackson

The order aims to eliminate the gap between small molecules and biologics in terms of the time to IRA-mandated Medicare negotiations, but pharma’s gain could be offset by other directives.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

More from Business

In Brief: Synthetic Design Lab Debuts With $20m To Advance Cutting-Edge ADCs

 
• By Sushmita Panda

As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

 
• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.